REAFREE® 6846

POWDER COATINGS / HYBRID

Product Application details	Saturated carboxylated polyester suitable for the formulation of decorpowders in combination with epoxy resins. Specially designed for low temperature curing.	orative and protective thermosetting	
Performance Benefits	Good flow.High salt spray resistance.Good mechanical properties.Good recoatability.		
Polymer Type	Saturated Carboxylated Polyester Resin		
Sales Specifications	Colour (50%), (ASTM D-1544)	3 max	
	Acid value, mg KOH/g (ASTM D-1639)	68 - 77	
	Viscosity 165°C, Pa.s (ICI – DIN 53229)	8 - 17	
Other	Appearance	Pale granules	
	Glass Transition T, ^o C (DSC - Tg)	approx 60°C	
Characteristics ¹	1 The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications		
Curing Conditions	15 minutes at 140°C (object temperature)		

Recommended **Mixing Ratio**

REAFREE 6846 / Epoxy : 50/50

Starting Formulation

REAFREE 6846	360
Titanium Dioxide(1)	265
Epoxy resins(2)	360
Flow modifier(3)	10
Benzoin	5

Kronos 2160
Araldite GT-7004 (Huntsman) DER 663 UE (Dow Chemical) Epikote 3003 (Resolution)
Byk 360 P (Byk Chemie)

Formulation **Guidelines**

Application / Extrusion Co	onditions
Extruder:	BUSS PCS-30
Torque:	40%
Speed:	200 rpm
Extrusion temperature:	80°C
Spraying Gun:	GEMA PG 1-B
Application voltage:	60-80 Kv
Test substrate:	Degreased
	steel 1 mm
Coating Properties	
Film thickness	60-80 microns
Gloss 60°, (ASTM D-523-60E)	Over 90%
Cupping test, (DIN 53156)	Over 8 mm
Direct Impact, (ASTM D-2794)	Over 80 Kg.cm
Reverse Impact, (ASTM D-2794)	Over 80 Kg.cm
Conical mandrel, (ASTM D-522)	100%
Adhesion, (DIN 53151)	Gt0



Product Safety	Please refer to the corresponding Safety Data Sheet.	
Delivery form	Granules. White opaque polyethylene bags of 25 Kg. One Ton pallet shrink – wrapped.	
Storage & Handling	The resin in its original unopened bags is stable for more than three years, stored in a dry place at temperature below 30°C. Avoid direct sunlight.	

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsability/responsible-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not to be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the component authority, and the treating physician.

Headquarter

ARKEMA FRANCE 420 rue d'Estienne d'Orves 92705 Colombes Cedex – France Tel : +33 (0)1 49 00 80 80 Arkema.com - arkemacoatingresins.com ARKEMA QUÍMICA, S.A.U. CTRA. OLZINELLES, S/N E08470 SANT CELONI (BCN) – ESPAÑA Tel: + 34 93 867 40 00

